Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma
Immune checkpoint inhibitors (ICI) have improved survival of patients with metastatic melanoma but can induce autoimmunologic side effects. Ye et al. report a retrospective analysis that further supports the finding that these are biomarkers for patients’ clinical benefit. Thereby, patients with imm...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2022
|
| In: |
British journal of cancer
Year: 2022, Volume: 126, Issue: 2, Pages: 163-164 |
| ISSN: | 1532-1827 |
| DOI: | 10.1038/s41416-021-01390-1 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41416-021-01390-1 Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41416-021-01390-1 
|
| Author Notes: | Jessica C. Hassel |
| Summary: | Immune checkpoint inhibitors (ICI) have improved survival of patients with metastatic melanoma but can induce autoimmunologic side effects. Ye et al. report a retrospective analysis that further supports the finding that these are biomarkers for patients’ clinical benefit. Thereby, patients with immune-related adverse events show a differential gene expression in chemokine-mediated signalling. |
|---|---|
| Item Description: | Gesehen am 14.09.2023 Online veröffentlicht: 25. Oktober 2021 |
| Physical Description: | Online Resource |
| ISSN: | 1532-1827 |
| DOI: | 10.1038/s41416-021-01390-1 |